



Clinical trial results:

A Prospective, International, Multicenter, Open-Label, Non-Controlled Study of Safety and Effectiveness of Palivizumab, in Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus

Summary

EudraCT number	2016-000221-39
Trial protocol	Outside EU/EEA
Global end of trial date	13 July 2017

Results information

Result version number	v1 (current)
This version publication date	25 January 2018
First version publication date	25 January 2018

Trial information

Trial identification

Sponsor protocol code	M15-539
-----------------------	---------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02968173
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	AbbVie Deutschland GmbH & Co.KG
Sponsor organisation address	AbbVie House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, United Kingdom, SL6-4UB
Public contact	Joaquin Valdes MD, AbbVie, joaquin.m.valdes@abbvie.com
Scientific contact	Joaquin Valdes MD, AbbVie, joaquin.m.valdes@abbvie.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	13 July 2017
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	13 July 2017
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To collect further data on safety and effectiveness of the liquid formulation of palivizumab (Synagis®) administered as monthly intramuscular injections among preterm infants, infants with chronic lung disease (CLD) of prematurity and infants with hemodynamically significant congenital heart disease (CHD)

Protection of trial subjects:

Participant and/or legal guardian read and understood the information provided about the study and gave written permission.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	09 November 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Belarus: 7
Country: Number of subjects enrolled	Russian Federation: 43
Worldwide total number of subjects	50
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	50
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Subjects were screened for adherence in inclusion/exclusion criteria at The Baseline (Enrollment) Visit.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Children at High Risk of Severe RSV Infection
------------------	---

Arm description:

A single intramuscular (IM) injection of palivizumab every 30 days beginning at Day 0 for a total of 3-5 injections determined by when in the RSV season a subject was enrolled.

Arm type	Experimental
Investigational medicinal product name	palivizumab
Investigational medicinal product code	
Other name	Synagis
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

All subjects were to receive 15 mg/kg of the liquid formulation of palivizumab administered by IM injection by the research staff or designee (health care professional) at the study site every 30 days for a minimum of 3 doses and a maximum of 5 doses.

Number of subjects in period 1	Children at High Risk of Severe RSV Infection
Started	50
Completed	49
Not completed	1
Consent withdrawn by subject	1

Baseline characteristics

Reporting groups

Reporting group title	Children at High Risk of Severe RSV Infection
-----------------------	---

Reporting group description:

A single intramuscular (IM) injection of palivizumab every 30 days beginning at Day 0 for a total of 3-5 injections determined by when in the RSV season a subject was enrolled.

Reporting group values	Children at High Risk of Severe RSV Infection	Total	
Number of subjects	50	50	
Age categorical Units: Subjects			
Age continuous Units: months arithmetic mean standard deviation	6.22 ± 4.428	-	
Gender categorical Units: Subjects			
Female	24	24	
Male	26	26	

End points

End points reporting groups

Reporting group title	Children at High Risk of Severe RSV Infection
Reporting group description: A single intramuscular (IM) injection of palivizumab every 30 days beginning at Day 0 for a total of 3-5 injections determined by when in the RSV season a subject was enrolled.	

Primary: Percentage of Subjects With RSV Hospitalization

End point title	Percentage of Subjects With RSV Hospitalization ^[1]
End point description: An RSV hospitalization is defined as either 1) a respiratory/cardiac hospitalization with a positive RSV test, 2) new onset of respiratory/cardiac symptoms in an already hospitalized child, with an objective measure of worsening respiratory/cardiac status and a positive RSV test, or 3) deaths, which can be demonstrated as caused by RSV (by autopsy or clinical history and virologic evidence).	
End point type	Primary
End point timeframe: Approximately 6 months	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics are presented, per protocol.

End point values	Children at High Risk of Severe RSV Infection			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: percentage of subjects				
number (confidence interval 95%)	0.0 (0.0 to 7.1)			

Statistical analyses

No statistical analyses for this end point

Secondary: Total Number of RSV-Hospitalization Days

End point title	Total Number of RSV-Hospitalization Days
End point description: All secondary outcome measures were dependent on RSV hospitalization. Since no subjects experienced an RSV hospitalization during the study, an evaluation of these outcome measures was not applicable.	
End point type	Secondary
End point timeframe: Approximately 6 months	

End point values	Children at High Risk of Severe RSV Infection			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[2]			
Units: days				

Notes:

[2] - no subjects experienced an RSV hospitalization during the study

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Who Received Supplemental Oxygen While Hospitalized

End point title	Percentage of Subjects Who Received Supplemental Oxygen While Hospitalized
-----------------	--

End point description:

Increased supplemental oxygen is defined as a new requirement or an increase in supplemental oxygen from prior to the onset of cardiac/respiratory symptoms.

All secondary outcome measures were dependent on RSV hospitalization. Since no subjects experienced an RSV hospitalization during the study, an evaluation of these outcome measures was not applicable.

End point type	Secondary
----------------	-----------

End point timeframe:

Approximately 6 months

End point values	Children at High Risk of Severe RSV Infection			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[3]			
Units: percentage of subjects				
number (not applicable)				

Notes:

[3] - no subjects experienced an RSV hospitalization during the study

Statistical analyses

No statistical analyses for this end point

Secondary: Total RSV-hospitalization Days With Increased Supplemental Oxygen Requirement

End point title	Total RSV-hospitalization Days With Increased Supplemental Oxygen Requirement
-----------------	---

End point description:

Increased supplemental oxygen is defined as a new requirement or an increase in supplemental oxygen from prior to the onset of cardiac/respiratory symptoms.

All secondary outcome measures were dependent on RSV hospitalization. Since no subjects experienced an RSV hospitalization during the study, an evaluation of these outcome measures was not applicable.

End point type	Secondary
End point timeframe:	
Approximately 6 months	

End point values	Children at High Risk of Severe RSV Infection			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[4]			
Units: days				

Notes:

[4] - no subjects experienced an RSV hospitalization during the study

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Intensive Care Unit (ICU) Admissions During RSV-hospitalization

End point title	Number of Intensive Care Unit (ICU) Admissions During RSV-hospitalization
-----------------	---

End point description:

All secondary outcome measures were dependent on RSV hospitalization. Since no subjects experienced an RSV hospitalization during the study, an evaluation of these outcome measures was not applicable.

End point type	Secondary
----------------	-----------

End point timeframe:

Approximately 6 months

End point values	Children at High Risk of Severe RSV Infection			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[5]			
Units: ICU admissions				

Notes:

[5] - no subjects experienced an RSV hospitalization during the study

Statistical analyses

No statistical analyses for this end point

Secondary: Total Days of RSV-ICU Stay

End point title	Total Days of RSV-ICU Stay
-----------------	----------------------------

End point description:

All secondary outcome measures were dependent on RSV hospitalization. Since no subjects experienced an RSV hospitalization during the study, an evaluation of these outcome measures was not applicable.

End point type	Secondary
End point timeframe:	
Approximately 6 months	

End point values	Children at High Risk of Severe RSV Infection			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[6]			
Units: days				

Notes:

[6] - no subjects experienced an RSV hospitalization during the study

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Who Received Mechanical Ventilation

End point title	Percentage of Subjects Who Received Mechanical Ventilation
End point description:	
All secondary outcome measures were dependent on RSV hospitalization. Since no subjects experienced an RSV hospitalization during the study, an evaluation of these outcome measures was not applicable.	
End point type	Secondary
End point timeframe:	
Approximately 6 months	

End point values	Children at High Risk of Severe RSV Infection			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[7]			
Units: percentage of subjects				
number (not applicable)				

Notes:

[7] - no subjects experienced an RSV hospitalization during the study

Statistical analyses

No statistical analyses for this end point

Secondary: Total Days of Mechanical Ventilation During RSV-hospitalization

End point title	Total Days of Mechanical Ventilation During RSV-hospitalization
End point description:	
All secondary outcome measures were dependent on RSV hospitalization. Since no participants experienced an RSV hospitalization during the study, an evaluation of these outcome measures was not applicable.	

End point type	Secondary
End point timeframe:	
Approximately 6 months	

End point values	Children at High Risk of Severe RSV Infection			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[8]			
Units: days				

Notes:

[8] - no subjects experienced an RSV hospitalization during the study

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

From first dose of study treatment through the last prophylaxis visit (up to Day 120 [± 5 days]) + 30 days (+5 days) and 100 days (+5 days)

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20.0
--------------------	------

Reporting groups

Reporting group title	PALIVIZUMAB TEAE Within 30 Days
-----------------------	---------------------------------

Reporting group description:

A single IM injection of palivizumab every 30 days beginning at Day 0 for a total of 3-5 injections determined by when in the RSV season a subject was enrolled.

Treatment-emergent adverse events (TEAEs) are defined as those that began after the first dose of study drug but within 30 days (+ 30 day assessment period) after the last dose of study drug.

Reporting group title	PALIVIZUMAB TEAE Within 100 Days
-----------------------	----------------------------------

Reporting group description:

A single IM injection of palivizumab every 30 days beginning at Day 0 for a total of 3-5 injections determined by when in the RSV season a subject was enrolled.

TEAEs are defined as those that began after the first dose of study drug but within 100 days (+ 100 day assessment period) after the last dose of study drug.

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: No subjects had a non-serious adverse event above the 5% threshold.

Serious adverse events	PALIVIZUMAB TEAE Within 30 Days	PALIVIZUMAB TEAE Within 100 Days	
Total subjects affected by serious adverse events			
subjects affected / exposed	6 / 50 (12.00%)	6 / 50 (12.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Haemangioma			
subjects affected / exposed	1 / 50 (2.00%)	1 / 50 (2.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Tachycardia paroxysmal			
subjects affected / exposed	1 / 50 (2.00%)	1 / 50 (2.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			

Bronchitis			
subjects affected / exposed	1 / 50 (2.00%)	1 / 50 (2.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis viral			
subjects affected / exposed	1 / 50 (2.00%)	1 / 50 (2.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasopharyngitis			
subjects affected / exposed	1 / 50 (2.00%)	1 / 50 (2.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	1 / 50 (2.00%)	1 / 50 (2.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection viral			
subjects affected / exposed	1 / 50 (2.00%)	1 / 50 (2.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	PALIVIZUMAB TEAE Within 30 Days	PALIVIZUMAB TEAE Within 100 Days	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 50 (0.00%)	0 / 50 (0.00%)	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
25 May 2016	Protocol Amendment 1 modified the study objective to reflect the large amount of data already available for the study drug.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported